Treating KRAS G12C Mutations

preview_player
Показать описание
Support for this educational program provided by Amgen.
  1. American Lung Association
  2. lung cancer
  3. KRAS
  4. pill
  5. targeted therapy
  6. immunotherapy
Рекомендации по теме
Treating KRAS G12C 0:01:42

Treating KRAS G12C Mutations

Current treatment strategies 0:01:10

Current treatment strategies KRASG12C–mutated NSCLC

How do doctors 0:02:31

How do doctors treat lung cancer with KRAS mutations?

Treatment strategies for 0:01:37

Treatment strategies for KRAS-mutant NSCLC with co-mutations

Targeting non-G12C KRAS 0:01:10

Targeting non-G12C KRAS mutations in NSCLC

Understanding NSCLC Treatment 0:04:43

Understanding NSCLC Treatment When You Have a KRAS Mutation

Treatment for KRAS 0:07:44

Treatment for KRAS G12C Mutated NSCLC with High Tumor Mutational Burden -Case-Based Panel Discussion

Lung Cancer Treatments 0:03:46

Lung Cancer Treatments for KRAS Mutation

Unlock KRAS G12C 0:49:07

Unlock KRAS G12C for lung cancer treatment decisions

Terri - How 0:01:34

Terri - How has your KRAS mutation affected the treatment options available to you?

Sotorasib outperforms docetaxel 0:02:59

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson

Sotorasib vs. Adagrasib 0:04:13

Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutated NSCLC - Case Based Panel Discussion

Sotorasib shows as 0:04:19

Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC

ASCO 2021 Lung 0:05:26

ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation

KRAS G12C Inhibition 0:07:51

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Challenges in targeting 0:01:09

Challenges in targeting KRASG12C mutations

Advances in managing 0:01:05

Advances in managing KRASG12C- and EGFR-mutated NSCLC

Challenges of KRAS-targeting 0:01:25

Challenges of KRAS-targeting for lung cancer therapy

Sotorasib for KRAS 0:06:33

Sotorasib for KRAS G12C-Mutated Lung Cancer

Sotorasib: first targeted 0:00:57

Sotorasib: first targeted approval for KRAS G12C mutated NSCLC

Advances in the 0:02:12

Advances in the management of KRAS-mutant NSCLC

KRAS G12C Emerges 0:00:50

KRAS G12C Emerges as New Potential Target in Non-Small Cell Lung Cancer

KRAS Biomarker Lung 0:08:18

KRAS Biomarker Lung Cancer: Treatment Options Explained

What is a 0:01:11

What is a KRAS mutation?